Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Jan 2020

Gerber David E, Camidge D Ross, Morgensztern Daniel, Cetnar Jeremey, Kelly Ronan J, Ramalingam Suresh S, Spigel David R, Jeong Woondong, Scaglioni Pier P, Zhang Song, Li Marilyn, Weaver David T, Vaikus Louis, Keegan Mitchell, Horobin Joanna C, Burns Timothy F

Abstract excerpt

OBJECTIVES: KRAS mutations, which occur in approximately 25% of lung adenocarcinoma cases, represent a major unmet clinical need in thoracic oncology. Preclinical studies have demonstrated that KRAS mutant NSCLC cell lines and xenografts with additional alterations in either TP53 or CDKN2A (INK4A/ARF) loci are sensitive to focal adhesion kinase (FAK) inhibition. Defactinib (VS-6063) is a selective oral inhibitor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Focal Adhesion Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyrazines

Share to Salvage Therapy

Share to Sulfonamides

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 31739184
DOI: 10.1016/j.lungcan.2019.10.033
PMCID: PMC6942685

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.PMID 31739184Read ↗

FAK-targeting PROTAC demonstrates enhanced antitumor activity against KRAS mutant non-small cell lung cancer.Semantic proximity Read ↗

Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.Semantic proximity Read ↗

Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancerSemantic proximity Read ↗

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC.Semantic proximity Read ↗

Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer.Semantic proximity Read ↗

ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer.Semantic proximity Read ↗

RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung AdenocarcinomasSemantic proximity Read ↗

Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer.Semantic proximity Read ↗

FAK signaling in human cancer as a target for therapeuticsSemantic proximity Read ↗

Avutometinib and Defactinib: First Approval.Semantic proximity Read ↗

Phosphorylation of FADD by the kinase CK1α promotes KRASG12D-induced lung cancer.Semantic proximity Read ↗

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.